N/A N=15 Effect of Sulforaphane in Broccoli Sprouts on Nrf2 Activation
Cystic Fibrosis
Primary: Nrf2 Activation in Nasal Epithelial Cells — 0; 0; 4; 4 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=239 Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects.
Meningococcal Disease
Primary: Percentages of Subjects With Serum Bactericidal Activity Using Human Complement (hSBA) Titers ≥ 5 for B Indicator Strains (H44/76, 5/99, and NZ98/254) and M10713 Strain…
Phase 3 N=30 BAX 326 Surgery Study in Hemophilia B Patients
Hemophilia B
Primary: Intraoperative Hemostatic Efficacy — 37; 20; 17; 1 surgeries
Phase 1 N=17 Effect of SCH 497079 on Metabolic Parameters and Influence of Race/Ethnic Origin on Therapeutic Response (Study P05338)(COMPLETED)
Type 2 Diabetes Mellitus
Primary: Pharmacodynamic: Change From Baseline in Mean 24-hour Plasma Glucose (AUC/Duration) at Week 4 (Part 1 - United States) — -4.27; 0.13; -53.8 mg/dL — p=0.5269
N/A N=115,397 Combined Bronchodilators in Chronic Obstructive Pulmonary Disease and the Risk of Adverse Cardio-pulmonary Events
Pulmonary Disease, Chronic Obstructive
Primary: Myocardial Infarction — 10.1; 11.3 No. of incident MI/1000patients/ year
Phase 2 N=30 Use of Low Dose Ketoconazole in Prostate Cancer That Does Not Respond to Hormone Therapy and Prior Chemotherapy
Prostate Cancer
Primary: Prostate Specific Antigen (PSA) Response (>50% Reduction From Baseline) — 14 Participants
N/A N=65,205 National Cooperative Growth Study (NCGS): A Post-marketing Surveillance Program for Nutropin, Nutropin AQ, Nutropin Depot, and Protropin
Growth Disorders
Primary: Number of Participants Who Died — 14; 96; 4; 7 participants
Phase 2 N=300 Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT)
Acute Heart Failure
Primary: Global Ranking of Predefined Events — 145.5; 155.7 rank — p=0.3087
N/A N=59 Nasal Epithelial Cells/Blood Lymphocyte Markers for Cystic Fibrosis (CF)/CF Pulmonary Exacerbations
Cystic Fibrosis
Primary: The Number of Participants With Blood and Sputum Samples Collected — 18; 27; 0; 14 Participants
N/A N=30 Flow Mediated Dilation in Response to Black Tea
Vascular Function
Primary: Flow Mediated Dilation — 5.24; 5.02; 6.05; 5.74 percentage of change in diameter — p=0.43
Phase 3 N=1,729 Long-term Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Fixed-Dose Combination
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Change From Baseline in 1-hour Morning Post-dose Forced Expiratory Volume in One Second (FEV1) — -0.030; 0.269; 0.213; 0.144 Liters — p=<0.0001
Phase 2 N=92 Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: A Phase 2 Study in the Old World
Cutaneous Leishmaniasis
Primary: Complete Clinical Response (CCR) of Lesion at Days 50, 100 and 180 (+7 Days) — 47; 30; 3; 12 Participants
Phase 3 N=77 Phase 2/3 Study of IGSC, 20% in PIDD
Primary Immunodeficiency Diseases (PID)
Primary: Rate of Acute Serious Bacterial Infections Per Year (ASBI) — 0.012 Estimated infections/ year — p=<0.0001
Phase 3 N=112 Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina
Chronic Myocardial Ischemia · Refractory Angina Pectoris · Advanced Coronary Heart Disease
Primary: Change From Baseline in Total Exercise Time on Exercise Tolerance Test (ETT) Using the Modified Bruce Protocol — 108.7; 90.0 seconds
N/A N=59 Changes in Subjects With Posterior Capsule Tightness
Shoulder Pain
Primary: Scapular Kinematics at 4weeks (Pre and Post Treatment) — 34.58; 36.00; 34.76; 35.72 degrees